Seed-based oral vaccines as allergen-specific immunotherapies

Human Vaccines

Volumn 7, Issue 3, 2011, Pages 357-366

  Takaiwa, Fumio ^a  

^a NATIONAL INSTITUTE OF AGROBIOLOGICAL SCIENCES   (Japan)

Author keywords

Allergen specific immunotherapy; Allergy vaccine; Oral tolerance; Pollen allergy; Seed based oral vaccine

Indexed keywords

ALLERGEN; HISTAMINE; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; PEPTIDE VACCINE; POLLEN ANTIGEN; VACCINE;

ALLERGENICITY; ALLERGIC DISEASE; ASTHMA; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; HISTAMINE RELEASE; HOUSE DUST ALLERGY; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INTESTINE LYMPHATIC TISSUE; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MUCOSAL IMMUNITY; NONHUMAN; PLANT BIOTECHNOLOGY; PLANT SEED; POLLEN ALLERGY; REPEATED DRUG DOSE; REVIEW; RICE; SKIN ALLERGY; T LYMPHOCYTE;

ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, PLANT; ANTIGENS, VIRAL; CRYPTOMERIA; DESENSITIZATION, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; GENE EXPRESSION REGULATION, PLANT; GENETIC VECTORS; HUMANS; ORYZA SATIVA; PLANT PROTEINS; PLANTS, GENETICALLY MODIFIED; PYROGLYPHIDAE; RECOMBINANT PROTEINS; RHINITIS, ALLERGIC, SEASONAL; SEED STORAGE PROTEINS; SEEDS; TH2 CELLS; VACCINES;

EID: 79953698171     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.3.14302     Document Type: Review

References (81)

1. Gerth vanWijk R. Allergy: a global problem. Allergy 2002; 57:1097-110.
2. Devereux G. The increase in the prevalence of asthma: food for thought. Nat Rev Immunol 2006; 6:869-74. (Pubitemid 44631655)
3. Woodfolk JA. MBChB. T-cell responses to allergens. J Allergy Clin Immunol 2007; 119:280-94.
4. Bousquet J, Lockey RF, Malling HU. Allergen immunotherapy: therapeutic vaccines for allergic diseases. WHO position paper. Allergy 1998; 53:1-42. (Pubitemid 28346358)
5. Frew AJ. Immunotherpy of allergic diseases. J Allergy Clin Immunol 2003; 111:712-9.
6. Noon L. Prophylactic inoculation against hay fever. Lancet 1911; 2:1572-3.
7. Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol 2008; 8:218-30. (Pubitemid 351323290)
8. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nature Rev Immunol 2006; 6:761-6.
9. Mann JFS, Acevedo R, del Campo J, Perez O, Ferro VA. Delivery systems: a vaccine strategy for overcoming mucosal tolerance? Expert Rev Vaccines 2009; 8:103-12.
10. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006;6:148-58. (Pubitemid 43361590)
11. McGhee JR, Michalek SM, Kiyono H. Mucosal immunoregulation environmental liposaccharide and GALT T lyomocytes regulate the IgA response. Microbiol Immunol 1984; 28:261-80. (Pubitemid 14126541)
12. Takahashi I, Mochi T, Yuki Y, Kiyono H. New horizon of mucosal immunity and vaccines. Curr Opin Immunol 2009; 21:352-8.
13. Weiner HL, Friedman A, Miller A, Khoury SJ, al-Sabbagh A, Santos L, et al. Oral tolerance immunologic mechanisms and treatment of animal and human organspecific autoimmune diseases by oral administration of autoantigens. Ann Rev Immunol 1994; 12:809-37.
14. Streatfiled SJ. Mucosal immunization using recombinat plant-based oral vaccines. Methos 2006; 38:150-7.
15. + and double-negative Peyr's patch dendric cells. J Immuno 2001; 166:4884-90.
16. Kunisawa J, Nochi T, Kiyono H. Immunological commonalities and distinctions between airway and digestive immunity. Trends Immunol 2008; 29:505-13.
17. Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007; 317:256-60. (Pubitemid 47076203)
18. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukku M, et al. Reciprocal developmental pathways for generation of pathogenic effector Th17 and regulatory T cells. Nature 2006; 441:235-8.
19. Awasthi A, Carrier Y, Peron JPS, Bettelli E, Kamanaka M, Flavell RA, et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nature Immunol 2007;12:1380-9. (Pubitemid 350131175)
20. Mucida D, Salek-Ardakani S. Regulation of Th17 cells in the mucosal surfaces. J Allergy Clin Immuno 2009;123:997-1003.
21. Mayer L, Shao L. Therpeutic potential of oral tolerance. Nature Rev Immunol 2004; 4:407-19.
22. Burks AW, Laubach S, Jones SM. Oral tolerance, food allergy and immunotherapy: Implications for future treatment. J Allergy Clin Immunol 2008; 121:1344-50.
23. Weiner HL. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immuno Today 1997; 18:335-43. (Pubitemid 27314470)
24. Faria AM, Weiner HL. Oral tolerance. Immunol Rev 2005; 206:232-59. (Pubitemid 41105174)
25. Whitacre CC, Gienapp IE, Orosz, CG, Bitar DM. Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy. J Immunol 1991;147:2155-63.
26. Chen Y, Inobe J, Marks R, Gonnella P, Kuchroo VK, Weiner HL. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 1995; 376:177-80.
27. Appeman LJ, Boussiotis VA. T cell anergy and costimulation. Immuno Rev 2003; 192:161-80. (Pubitemid 36613331)
28. Greenwald RJ, Freeman GJ, Sharpe AH. B7 family revised. Annu Rev Immunol 2005; 23:515-48.
29. Marth T, Zeitz Z, Ludviksson B, Strober W, Kesall B. Murine model of oral tolerance. Induction of Fas-mediated apotosis by blockable of interleukin-12. Ann NY Acad Sci 1998; 859:290-4.
30. Chen Y, Kuchroo VK, Inob J, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994; 265:1237-40. (Pubitemid 24291983)
31. + regulatory T cells by oral antigen administration. J Immunol 2001; 167:4245-53.
32. Verhagen J, Blaser K, Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy: T-regulatory cells and more. Immunol Allergy Clin N Am 2006;26:207-31.
33. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol 2004; 113:1024-34.
34. Akdis M, Akids CA. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2007;119:780-9. (Pubitemid 46527830)
35. Ozdemir C, Akids M, Akids CA. T regulatory cells and their counterparts: masters of immune regulation. Clin Exper Allergy 2009; 39:626-39.
36. Rybicki EP. Plan-made vaccines for humans and animals. Plant Biotech J 2010; 8:620-37.
37. Yosibov V, Rabindran S. Recent progress in the development of plant-derived vaccines. Exp Rev vaccine 2008; 7:1173-83.
38. Daniell H, Singh ND, Mason H, Streatfield SJ. Plant-made vaccine antigens and biopharmaceuticals. Trends Plant Sci 2009; 14:669-79.
39. Twymann RM, Stoger E, Schillberg S, Christou P, Fischer R. Molecular farming in plants: host systems and expression technology. Trends Biotech 2003;21:570-8. (Pubitemid 37415010)
40. Boothe J, Nykiforuk C, Shen Y, Zaplachinski S, Szarka S, Kuhlman P, et al. Seed-based expression systems for plant molecular farming. Plant Biotech J 2010; 8:588-606.
41. Stoger E, Ma JKC, Fischer P, Christou P. Sowing the seeds of success: pharmaceutical proteins from proteins. Cur Opin Biotech 2005; 16:167-73.
42. Shewry P, Halford NG. Cereal seed storage proteins: structures, properties and role in grain utilization. J Exp Botany 2002; 53:370.
43. Takaiwa F, Takagi H, Hirose S, Wakasa Y. Endosperm tissue is good production platform for artificial recombinant proteins in transgenic rice. Plant Biotech J 2007;5:84-92. (Pubitemid 46006530)
44. Streatfield SJ. Approaches to achieve high-level heterogous protein production in plants. Plant Biotech J 2007; 5:2-15. (Pubitemid 46006523)
45. Takaiwa F. Transgenic rice seed as a nutriceutical delivery system. CAB reviews: perspectives in agriculture, veterinary science. Nutr Nat Resour 41:9.
46. Qu LQ, Takaiwa F. Tissue specific expression and quantitative potential evaluate of seed storage component gene promoters in transgenic rice. Plant Biotch J 2004; 2:113-25. (Pubitemid 40199460)
47. Gomrd V, Fitchette AC, Menu-Bouaouiche L, Saintjore-Dupas C, Plasson C, Michaud D, et al. Plant-specific glycosylation patterns in the context of therapeutic protein production. Plant Biotech J 2010; 8:564-87.
48. Benchabane M, Goulet C, Rivard D, Faye L, Gomord V, Michaud D. Preventing unintended proteolysis in plant protein biofactories. Plant Biotech J 2008; 6:633-48.
49. Vitale A, Hinz G. Sorting of proteins to storage vacuoles: how many mechanisms? Trends Plant Sci 2005; 10:315-23.
50. Chikawamba R, Scott MR, Mejia LB, Marson HS, Wang K. Localization of a bacterial protein in starch granules of transgenic maize kernels. Proc Natl Acad Sci USA 2003; 100:11127-32. (Pubitemid 37140163)
51. Drakakaki G, Marcel S, Arcalis E, Gonzalez-Melendi P, Fischer R, Christou P, et al. The intracellular fate of a recombinant protein is tissue dependent. Plant Physiol 2006; 141:578-86.
52. Takaiwa F, Hirose S, Takagi H, Yang L, Wakasa Y. Deposition of a recombinant peptide in ER-derived protein bodies by retention with cysteine-rich prolamins in transgenic rice seed. Planta 2009; 229:1147-58.
53. Linhart B, Valenta R. Molecular design of allergy vaccines. Cur Opin Immunol 2005; 17:546-55.
54. Niederberger V, Valent R. Molecular approaches for new vaccines against allergy. Expert Rev Vaccines 2006; 5:103-10.
55. Valenta R, Niederberger V. Recombinant allergens for immunotherapy. J Allergy Clin Immunol 2007; 119:826-30. (Pubitemid 46527833)
56. Mutschlechner S, Deifl S, Bohle B. Genetic allergen modification in the development of novel approaches to specific immunotherapy. Clin Exp Allergy 2009; 39:1635-42.
57. Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomized controlled trial. Lancet 2002; 360:47-53. (Pubitemid 34756492)
58. Schramm G, Kahlert H, Suck R, Weber B, Stuwe HT, Muller WD, et al. "Allergen engineering": variant of the timothy grass pollen allergen Phl p 5b with reduced IgE-binding capacity but conserved T cell reactivity. J Immunol 1999; 162:2406-14.
59. Swoboda I, De Weerd N, Bhalla PL, Niederberger V, Sperr WR, Valent P, et al. Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapy. Eur J Immunol 2002; 32:270-80.
60. Westritschnig K, Focke M, Verdino P, Goessler W, Keller W, Twardosz A, et al. Generation of an allergy vaccine by disruption of the three-dimensional structure of the cross-reactive calcium-binding allergen, Phl p 7. J Immunol 2004; 172:5684-92.
61. Takai T, Yokota T, Yasue M, Nishiyama C, Yuuki T, Mori A, et al. Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy. Nature Biotech 1997; 15:7548.
62. Drew AC, Eusebius NP, Kenins L, de Silva HD, Suphioglu C, Rolland JM, et al. Hypoallergenic variants of the major latex allergen Hev b 6.01 retaining human T lymphocyte reactivity. J Immunol 2004; 173:5872-9. (Pubitemid 39392178)
63. Ball T, Linhart B, Sonneck, Blatt K, Herrmann H, Valent P, et al. Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination. Allergy 2009; 64:569-80.
64. Mothes-Luksch N, Stumvoll S, Linhart B, Focke M, Krauth MT, Hauswirth AV, et al. Distruption of allergenic activity of the major grass pollen allergen Phl p 2 by reassembly as a mosaic protein. J Immuol 2008; 181:4864-73.
65. Vrtala S, Hirtenlehner K, Vangelista L, Pastore A, Eichler HG, Sperr WR, et al. Conversion of the major birch pollen allergen, Bet v 1, into two non anapylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest 1997; 99:1673-81.
66. Vrtala S, Hirtenlehner K, Susani M, Akidis M, Kussebi F, Akidis CA, et al. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J 2001; 15:2045-7.
67. Jutel M, Jager L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005; 116:608-13. (Pubitemid 41267135)
68. Ali FR, Larche M. Peptide-based immunotherapy: a novel strategy for allergic disease. Expert Rev Vaccines 2005; 4:881-9. (Pubitemid 43040908)
69. Larche M. Peptide immunotherapy for allergic diseases. Allergy 2007; 62:325-31.
70. Hirahara K, Saito S, Serizawa N, Sasaki R, Sakaguchi M, Inouye S, et al. Oral administration of a dominant T-cell determinant peptide inhibits allergen-specific TH1 and TH2 cell response in Cry j2-primed mice. J Allergy Clin Immunol 1998; 102:961-7. (Pubitemid 29018313)
71. Nochi T, Takagi H, Yuki Y, Yang L, Masumura T, Mejima M, et al. Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination. Proc Natl Acad Sci USA 2007; 104:10986-91. (Pubitemid 47175213)
72. Takagi H, Hiroi T, Hirose S, Yang L, Takaiwa F. Rice seed ER-derived protein body as an efficient delivery vehicle for oral tolerogenic peptides. Peptides 2010; 31:1421-5.
73. Takaiwa F. A rice-based edible vaccine expressing multiple T-cell epitopes to induce oral tolerance and inhibit allergy. Immuno Allergy Clin N Am 2007; 27:129-39. (Pubitemid 46185905)
74. Takagi H, Hiroi T, Yang L, Tada Y, Yuki Y, Takamura K, et al. A rice-based edible vaccine expressing multiple epitopes induces oral tolerance for inhibition of Th2-mediated IgE responses. Proc Natl Acad Sci USA 2005; 102:17525-30. (Pubitemid 41740899)
75. Hirahara K, Tatsuta T, Takatori T, Otsuka M, Kirinaka H, et al. Preclinical evaluation of an immunotherapeutic peptide comprising 7 T-cell determinants of Cry j 1 and Cry j 2, the major Japanese cedar pollen allergens. J Allergy Clin Immunol 2001; 108:94-100. (Pubitemid 32662238)
76. Takagi H, Saito S, Yang L, Nagasaka S, Nishizawa N, et al. Oral immunotherapy against a pollen allergy using a seed-based peptide vaccine. Plant Biotech J 2005; 3:521-33. (Pubitemid 44944506)
77. Takagi H, Hirose S, Yasuda H, Takaiwa F. Biochemical safety evaluation of transgenic rice seeds expressing T cell epitopes of Japanese cedar pollen allergens. J Agric Food Chem 2006; 54:9901-5. (Pubitemid 46158987)
78. Domon E, Takagi H, Hirose S, Sugita K, Kasahara S, Ebinuma H, et al. 26-week oral safety study in macaques for transgenic rice containing major human T-cell epitope peptides from Japanese cedar pollen allergens. Agric Food Chem 2009; 57:5633-8.
79. Yang L, Kajiura H, Suzuki K, Hirose S, Fijiyama K, Takaiwa F. Generation of a transgenic rice seed-based edible vaccine against house dust mite allergy. Bioch Biophy Res Comm 2008; 365:334-8.
80. Suzuki K, Kaminuma O, Yang L, Motoi Y, TakaiT, Ishikawa S, et al. Development of transgenic rice expressing mite antigen for a new concept of immunotherapy. Int Arch Allergy Immunol 2009; 149:21-4.
81. Suzuki K, Kaminuma O, Yang L, Takai T, Mori A et al. Prevention of allergic asthma by vaccination with transgenic rice seed expressing mite allergen: induction of allergen-specific oral tolerance without bystander suppression. Plant Biotech J 2011 (in press).